Association of sodium-glucose co-transporter-2 inhibitors with cardiac outcomes and mortality in cancer patients: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ...
MedPage Today on MSN
Popular Oral Drug for Diabetes May Hold 'Intriguing' Side Benefit
Type 2 diabetes patients starting on SGLT2 inhibitors had a sightly lower risk of autoimmune rheumatic diseases compared with ...
"Dapagliflozin reduced UACR compared with placebo, although considerable variability was observed among individuals. These variations, which were consistent after re-exposure, underscore the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback